

Noritoshi Kobayashi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6788939/publications.pdf>

Version: 2024-02-01

53
papers

1,324
citations

471509

17
h-index

361022

35
g-index

58
all docs

58
docs citations

58
times ranked

2183
citing authors

#	ARTICLE	IF	CITATIONS
1	FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis. <i>Clinical Cancer Research</i> , 2007, 13, 902-911.	7.0	385
2	Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study. <i>Clinical Cancer Research</i> , 2017, 23, 4625-4632.	7.0	150
3	Prognostic Value of Tumor Architecture, Tumor-Associated Vascular Characteristics, and Expression of Angiogenic Molecules in Pancreatic Endocrine Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 187-196.	7.0	85
4	Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. <i>Pancreatology</i> , 2019, 19, 127-135.	1.1	65
5	JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. <i>Journal of Gastroenterology</i> , 2021, 56, 1033-1044.	5.1	58
6	Clinical classification of congenital extrahepatic portosystemic shunts. <i>Hepatology Research</i> , 2010, 40, 585-593.	3.4	48
7	Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan. <i>Journal of Gastroenterology</i> , 2017, 52, 9-18.	5.1	48
8	Endoscopic ultrasonographic findings predict the risk of carcinoma in branch duct intraductal papillary mucinous neoplasms of the pancreas. <i>Pancreatology</i> , 2012, 12, 141-145.	1.1	38
9	Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. <i>Annals of Surgical Oncology</i> , 2019, 26, 1385-1393.	1.5	36
10	Endoscopic inside stent placement is suitable as a bridging treatment for preoperative biliary tract cancer. <i>BMC Gastroenterology</i> , 2015, 15, 8.	2.0	30
11	Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2275-2284.	2.8	26
12	Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 661-668.	2.3	25
13	Three-dimensional analysis of pancreatic fat by fat-water magnetic resonance imaging provides detailed characterization of pancreatic steatosis with improved reproducibility. <i>PLoS ONE</i> , 2019, 14, e0224921.	2.5	25
14	FOXP3+ Regulatory T Cells and Tumoral Indoleamine 2,3-Dioxygenase Expression Predicts the Carcinogenesis of Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Pancreatology</i> , 2010, 10, 631-640.	1.1	22
15	Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. <i>Cancer Science</i> , 2019, 110, 707-716.	3.9	22
16	Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 996-1007.	8.1	22
17	Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure. <i>Medicine (United States)</i> , 2017, 96, e6769.	1.0	20
18	Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups. <i>Pancreatology</i> , 2020, 20, 1421-1427.	1.1	18

#	ARTICLE	IF	CITATIONS
19	Complications of the treatment of endoscopic biliary strictures developing after liver transplantation. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2011, 18, 202-210.	2.6	16
20	Imaging Findings of Pancreatic Cystic Lesions in von Hippel-Lindau Disease. <i>Internal Medicine</i> , 2012, 51, 1301-1307.	0.7	15
21	Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. <i>Pancreas</i> , 2018, 47, 631-636.	1.1	15
22	Precision modeling of gall bladder cancer patients in mice based on orthotopic implantation of organoid-derived tumor buds. <i>Oncogenesis</i> , 2021, 10, 33.	4.9	13
23	Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma. <i>Cancer Science</i> , 2021, 112, 1936-1942.	3.9	12
24	Characterization of K-ras gene mutations in association with mucinous hypersecretion in intraductal papillary-mucinous neoplasms. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2008, 15, 169-177.	2.0	11
25	Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial. <i>Cancers</i> , 2022, 14, 2112.	3.7	11
26	Severe anaphylaxis caused by intravenous anti-cancer drugs. <i>Cancer Medicine</i> , 2021, 10, 7174-7183.	2.8	9
27	Duodenal gastrointestinal stromal tumor resembling a pancreatic neuroendocrine tumor in a patient with neurofibromatosis type I (von Recklinghausen's disease): a case report. <i>Journal of Medical Case Reports</i> , 2010, 4, 302.	0.8	8
28	Safety and efficacy of peptide receptor radionuclide therapy with ¹⁷⁷ Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1332-1341.	2.2	8
29	Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer. <i>Oncotarget</i> , 2019, 10, 1775-1784.	1.8	8
30	Neuroendocrine tumor theranostics. <i>Cancer Science</i> , 2022, 113, 1930-1938.	3.9	8
31	IgG4-related sclerosing cholangitis may be a risk factor for cancer. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 524-532.	2.6	7
32	Safety and response after peptide receptor radionuclide therapy with ¹⁷⁷ Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2022, 29, 487-499.	2.6	7
33	FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. <i>Pancreatology</i> , 2020, 20, 1519-1525.	1.1	6
34	Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 727-739.	2.6	5
35	Small Intestinal Metastasis From Carcinoma of the Lung. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, e103.	4.4	4
36	Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study. <i>Trials</i> , 2020, 21, 453.	1.6	4

#	ARTICLE	IF	CITATIONS
37	Primary Hepatic Neuroendocrine Carcinoma. Japanese Journal of Gastroenterological Surgery, 2017, 50, 9-17.	0.1	4
38	Development of a list of competencies and entrustable professional activities for resident physicians during death pronouncement: a modified Delphi study. BMC Medical Education, 2022, 22, 119.	2.4	4
39	Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms. Internal Medicine, 2023, 62, 159-167.	0.7	4
40	Rectal carcinoma with metachronous metastasis to the extrahepatic bile duct without liver tumor. Clinical Journal of Gastroenterology, 2011, 4, 278-282.	0.8	3
41	Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms. Internal Medicine, 2021, 60, 977-983.	0.7	3
42	Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake. Oncologist, 2021, 26, e1862-e1869.	3.7	2
43	Does primary site of colorectal cancer become a prognostic factor of patients undergoing curative resection of liver metastases?. Journal of Clinical Oncology, 2017, 35, 772-772.	1.6	2
44	A case of primary intestinal GIST diagnosed by double-balloon enteroscope. Progress of Digestive Endoscopy, 2007, 71, 94-95.	0.0	2
45	Detection rate of endoscopic ultrasound and computed tomography in diagnosing pancreatic neuroendocrine neoplasms including small lesions: A multicenter study. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, 29, 950-959.	2.6	2
46	Case reports: chemoradiotherapy for locally advanced neuroendocrine carcinoma of the gallbladder. Clinical Journal of Gastroenterology, 0, , .	0.8	2
47	Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors. Cancers, 2022, 14, 3317.	3.7	2
48	Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional Phenotype. Frontiers in Oncology, 2020, 10, 555963.	2.8	1
49	Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer.. Journal of Clinical Oncology, 2017, 35, 429-429.	1.6	1
50	A case of successful resection of the islet cell tumor of the pancreas during endoscopic nasopancreatic drainage (ENPD) before the operation. Progress of Digestive Endoscopy, 2005, 66, 100-101.	0.0	0
51	A case of multiple ulcers of the small intestine observed by capsule endoscopy and single-balloon enteroscopy. Progress of Digestive Endoscopy, 2012, 80, 116-117.	0.0	0
52	Retrospective analysis of Peptide Receptor Radionuclide Therapy (PRRT) in Japanese patients with unresectable neuroendocrine tumor.. Journal of Clinical Oncology, 2020, 38, e16700-e16700.	1.6	0
53	Prolonged survival in a patient with multiple liver metastases from a pancreatic neuroendocrine tumor treated with Peptide Receptor Radiotherapy (PRRT). Suizo, 2020, 35, 97-103.	0.1	0